Quincy S. Chu

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd et al. · The Lancet Oncology · 2016 · 632 citations

Non-small-cell Lung Cancer, Medicine, Pathology +9

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Charles M. Rudin, Christine L. Hann, Edward B. Garon et al. · Clinical Cancer Research · 2012 · 542 citations · Full text

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

Seth A. Wander, Ofir Cohen, Xueqian Gong et al. · Cancer Discovery · 2020 · 399 citations · Full text

Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy

Rachel A. Murphy, Marina Mourtzakis, Quincy S. Chu et al. · Cancer · 2011 · 275 citations